Kinled Holding has supported Aleva since its early stages
Kinled Holding has supported Aleva since its early stages
Kinled’s early backing enabled Aleva’s evolution from a university spin-off into a clinically validated MedTech company. Through ongoing support and board participation, Kinled contributes to the company’s strategic direction.
Kinled’s early backing enabled Aleva’s evolution from a university spin-off into a clinically validated MedTech company. Through ongoing support and board participation, Kinled contributes to the company’s strategic direction.
Context
Context
As part of Kinled’s MedTech portfolio, Aleva exemplifies the group’s approach to supporting technologies with both clinical validation and commercial scalability.
As part of Kinled’s MedTech portfolio, Aleva exemplifies the group’s approach to supporting technologies with both clinical validation and commercial scalability.
As part of Kinled’s MedTech portfolio, Aleva exemplifies the group’s approach to supporting technologies with both clinical validation and commercial scalability.
SHARED ENDEAVOURS
SHARED ENDEAVOURS
Strategic Investment & Governance
Strategic Investment & Governance
A relationship defined by aligned vision, mutual trust, and a commitment to turning research into commercial success.
Kinled Overview
Kinled Holding is an international investment group based in Switzerland and Hong Kong, specialising in life sciences, FinTech, and deep-tech ventures. Its portfolio includes companies in MedTech, biotechnology, and digital infrastructure across Europe and Asia.
Partnership Highlights
The collaboration between Kinled and Aleva extends beyond investment, combining strategic insight with active engagement in governance, market preparation, and technology positioning. Kinled’s multidisciplinary network across finance, MedTech, and innovation ecosystems continues to broaden Aleva’s access to strategic partners and international opportunities.
Kinled Overview
Kinled Holding is an international investment group based in Switzerland and Hong Kong, specialising in life sciences, FinTech, and deep-tech ventures. Its portfolio includes companies in MedTech, biotechnology, and digital infrastructure across Europe and Asia.
Partnership Highlights
The collaboration between Kinled and Aleva extends beyond investment, combining strategic insight with active engagement in governance, market preparation, and technology positioning. Kinled’s multidisciplinary network across finance, MedTech, and innovation ecosystems continues to broaden Aleva’s access to strategic partners and international opportunities.
“Aleva exemplifies how rigorous engineering and clinical evidence can come together to redefine what’s possible in neurotechnology.”
“Aleva exemplifies how rigorous engineering and clinical evidence can come together to redefine what’s possible in neurotechnology.”
Patrik Aisher - Kinled's Chairman
Patrik Aisher - Kinled's Chairman
“Aleva exemplifies how rigorous engineering and clinical evidence can come together to redefine what’s possible in neurotechnology.”
Patrik Aisher - Kinled's Chairman
Impact & Shared Achievements
The collaboration between Kinled and Aleva has been mutually reinforcing — pairing Aleva’s technological depth with Kinled’s strategic reach. Together, they have built a model of science-backed investment that demonstrates how disciplined capital and clinical innovation can advance the field of neuromodulation while creating sustainable long-term value.
Impact & Shared Achievements
The collaboration between Kinled and Aleva has been mutually reinforcing — pairing Aleva’s technological depth with Kinled’s strategic reach. Together, they have built a model of science-backed investment that demonstrates how disciplined capital and clinical innovation can advance the field of neuromodulation while creating sustainable long-term value.